HRP20020008A2 - Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use - Google Patents

Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use Download PDF

Info

Publication number: HRP20020008A2
Authority: HR; Croatia
Prior art keywords: image; amino; aryl; heteroaryl; formula
Prior art date: 1999-06-04

Application number

HR20020008A

Other languages

English (en)

Croatian (hr)

Inventor

Chu Shao Song

Larry Andrew Alegria

Steven Lee Bender

Suzanne Benedict Pritchett

Allen J Borchardt

Robert Steve Kania

Mitchell Davis Nambu

Anna Maria Tempczyk-Russell

Sarshar Sepehr

Bhumralkar Dilip

Peng Zhengwei

Michelle Yang Yi

Original Assignee

Agouron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-04

Filing date

2002-01-04

Publication date

2004-02-29

2002-01-04 Application filed by Agouron Pharma filed Critical Agouron Pharma

2004-02-29 Publication of HRP20020008A2 publication Critical patent/HRP20020008A2/hr

Links

238000000034 method Methods 0.000 title claims description 42
102000001253 Protein Kinase Human genes 0.000 title claims description 29
108060006633 protein kinase Proteins 0.000 title claims description 29
230000002401 inhibitory effect Effects 0.000 title description 7
239000008194 pharmaceutical composition Substances 0.000 title description 7
150000003557 thiazoles Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 139
125000003118 aryl group Chemical group 0.000 claims description 92
125000000217 alkyl group Chemical group 0.000 claims description 83
125000001072 heteroaryl group Chemical group 0.000 claims description 79
-1 cyano, amino Chemical group 0.000 claims description 56
230000000694 effects Effects 0.000 claims description 48
125000000753 cycloalkyl group Chemical group 0.000 claims description 44
229910052739 hydrogen Inorganic materials 0.000 claims description 42
239000001257 hydrogen Substances 0.000 claims description 40
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 39
150000003839 salts Chemical class 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 35
125000003545 alkoxy group Chemical group 0.000 claims description 29
229910052799 carbon Inorganic materials 0.000 claims description 24
239000002207 metabolite Substances 0.000 claims description 24
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
229910052757 nitrogen Inorganic materials 0.000 claims description 23
239000000651 prodrug Substances 0.000 claims description 23
229940002612 prodrug Drugs 0.000 claims description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
201000010099 disease Diseases 0.000 claims description 21
108091000080 Phosphotransferase Proteins 0.000 claims description 20
102000020233 phosphotransferase Human genes 0.000 claims description 20
229910052760 oxygen Inorganic materials 0.000 claims description 19
230000033115 angiogenesis Effects 0.000 claims description 18
230000004663 cell proliferation Effects 0.000 claims description 16
229910052717 sulfur Inorganic materials 0.000 claims description 16
125000003342 alkenyl group Chemical group 0.000 claims description 15
102000005962 receptors Human genes 0.000 claims description 10
108020003175 receptors Proteins 0.000 claims description 10
239000000460 chlorine Substances 0.000 claims description 9
230000001404 mediated effect Effects 0.000 claims description 9
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 7
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 claims description 6
229910052731 fluorine Inorganic materials 0.000 claims description 6
125000001475 halogen functional group Chemical group 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
125000004104 aryloxy group Chemical group 0.000 claims description 5
125000004093 cyano group Chemical group *C#N 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
125000003282 alkyl amino group Chemical group 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
125000004663 dialkyl amino group Chemical group 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 4
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 3
125000000547 substituted alkyl group Chemical group 0.000 claims description 3
125000003107 substituted aryl group Chemical group 0.000 claims description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
125000004442 acylamino group Chemical group 0.000 claims description 2
125000006574 non-aromatic ring group Chemical group 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
229910052703 rhodium Inorganic materials 0.000 claims description 2
125000006413 ring segment Chemical group 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims 18
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
108091008605 VEGF receptors Proteins 0.000 claims 1
230000004614 tumor growth Effects 0.000 claims 1
238000005160 1H NMR spectroscopy Methods 0.000 description 201
238000004364 calculation method Methods 0.000 description 149
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 120
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 106
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 76
239000000243 solution Substances 0.000 description 76
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 75
229910001868 water Inorganic materials 0.000 description 71
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 61
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 57
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 50
239000002904 solvent Substances 0.000 description 45
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
235000019439 ethyl acetate Nutrition 0.000 description 42
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 40
238000012360 testing method Methods 0.000 description 39
210000004027 cell Anatomy 0.000 description 38
CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 37
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 35
238000006243 chemical reaction Methods 0.000 description 34
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
239000003795 chemical substances by application Substances 0.000 description 29
206010028980 Neoplasm Diseases 0.000 description 28
201000011510 cancer Diseases 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
239000011541 reaction mixture Substances 0.000 description 21
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
239000002253 acid Substances 0.000 description 20
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 18
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 17
238000003556 assay Methods 0.000 description 17
239000002244 precipitate Substances 0.000 description 17
239000007787 solid Substances 0.000 description 17
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 16
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 16
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 15
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 15
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
108091007914 CDKs Proteins 0.000 description 14
102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 13
108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 13
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 13
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 12
238000000746 purification Methods 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
238000004252 FT/ICR mass spectrometry Methods 0.000 description 11
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
239000003112 inhibitor Substances 0.000 description 11
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 11
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
102000016736 Cyclin Human genes 0.000 description 10
108050006400 Cyclin Proteins 0.000 description 10
101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 10
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
238000004587 chromatography analysis Methods 0.000 description 10
238000001914 filtration Methods 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
229910052943 magnesium sulfate Inorganic materials 0.000 description 10
235000019341 magnesium sulphate Nutrition 0.000 description 10
230000008569 process Effects 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
238000004809 thin layer chromatography Methods 0.000 description 10
102100022014 Angiopoietin-1 receptor Human genes 0.000 description 9
101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
238000011161 development Methods 0.000 description 9
230000018109 developmental process Effects 0.000 description 9
235000018102 proteins Nutrition 0.000 description 9
235000017557 sodium bicarbonate Nutrition 0.000 description 9
229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 8
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 8
150000001412 amines Chemical class 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 8
150000001413 amino acids Chemical class 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
125000004432 carbon atom Chemical group C* 0.000 description 8
230000003197 catalytic effect Effects 0.000 description 8
229910001629 magnesium chloride Inorganic materials 0.000 description 8
239000003921 oil Substances 0.000 description 8
235000019198 oils Nutrition 0.000 description 8
239000000843 powder Substances 0.000 description 8
239000007858 starting material Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
102000003903 Cyclin-dependent kinases Human genes 0.000 description 7
108090000266 Cyclin-dependent kinases Proteins 0.000 description 7
102000003855 L-lactate dehydrogenase Human genes 0.000 description 7
108700023483 L-lactate dehydrogenases Proteins 0.000 description 7
102000013009 Pyruvate Kinase Human genes 0.000 description 7
108020005115 Pyruvate Kinase Proteins 0.000 description 7
230000022131 cell cycle Effects 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
235000003642 hunger Nutrition 0.000 description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
239000002609 medium Substances 0.000 description 7
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 7
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
239000000047 product Substances 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
230000037351 starvation Effects 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 6
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 6
108010068192 Cyclin A Proteins 0.000 description 6
102100025191 Cyclin-A2 Human genes 0.000 description 6
101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 6
230000009471 action Effects 0.000 description 6
KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
238000010828 elution Methods 0.000 description 6
210000002889 endothelial cell Anatomy 0.000 description 6
238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
210000001210 retinal vessel Anatomy 0.000 description 6
239000000758 substrate Substances 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
241000701447 unidentified baculovirus Species 0.000 description 6
125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
102100037813 Focal adhesion kinase 1 Human genes 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
241000700159 Rattus Species 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
230000035578 autophosphorylation Effects 0.000 description 5
230000006369 cell cycle progression Effects 0.000 description 5
238000004590 computer program Methods 0.000 description 5
125000000524 functional group Chemical group 0.000 description 5
125000005843 halogen group Chemical group 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
230000009467 reduction Effects 0.000 description 5
210000001525 retina Anatomy 0.000 description 5
238000010898 silica gel chromatography Methods 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229910052938 sodium sulfate Inorganic materials 0.000 description 5
235000011152 sodium sulphate Nutrition 0.000 description 5
239000000126 substance Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
102000006313 Cyclin D3 Human genes 0.000 description 4
230000005778 DNA damage Effects 0.000 description 4
231100000277 DNA damage Toxicity 0.000 description 4
230000012746 DNA damage checkpoint Effects 0.000 description 4
108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 4
102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 4
230000010190 G1 phase Effects 0.000 description 4
108010001336 Horseradish Peroxidase Proteins 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000004913 activation Effects 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
239000012267 brine Substances 0.000 description 4
150000004657 carbamic acid derivatives Chemical class 0.000 description 4
QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
239000003909 protein kinase inhibitor Substances 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
ZFOXYMYPSAEQEA-UHFFFAOYSA-N 4-amino-2-(4-sulfamoylanilino)-1,3-thiazole-5-carbothioamide Chemical compound NC1=C(C(=S)N)SC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 ZFOXYMYPSAEQEA-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
108010058546 Cyclin D1 Proteins 0.000 description 3
108010058545 Cyclin D3 Proteins 0.000 description 3
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
239000007832 Na2SO4 Substances 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
108050002653 Retinoblastoma protein Proteins 0.000 description 3
230000018199 S phase Effects 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000002491 angiogenic effect Effects 0.000 description 3
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
239000000969 carrier Substances 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000001035 drying Methods 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
230000012010 growth Effects 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
150000007529 inorganic bases Chemical class 0.000 description 3
238000002955 isolation Methods 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
229930029653 phosphoenolpyruvate Natural products 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
238000002953 preparative HPLC Methods 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
238000010992 reflux Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
230000007704 transition Effects 0.000 description 3
229910052727 yttrium Inorganic materials 0.000 description 3
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical group C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
OFFSPAZVIVZPHU-UHFFFAOYSA-N 1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC2=C1 OFFSPAZVIVZPHU-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
CKQHAYFOPRIUOM-UHFFFAOYSA-N 3'-Aminoacetophenone Chemical compound CC(=O)C1=CC=CC(N)=C1 CKQHAYFOPRIUOM-UHFFFAOYSA-N 0.000 description 2
QWPMAZSSDIEIAO-UHFFFAOYSA-N 3-[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]-n-[(2-methylpropan-2-yl)oxy]benzamide Chemical compound CC(C)(C)ONC(=O)C1=CC=CC(C=2N=C(CCl)ON=2)=C1 QWPMAZSSDIEIAO-UHFFFAOYSA-N 0.000 description 2
NMQCHSGVKUTKBH-UHFFFAOYSA-N 3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenol Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(O)C=CC=2)=C1 NMQCHSGVKUTKBH-UHFFFAOYSA-N 0.000 description 2
RMFKWWDNIKWLNN-UHFFFAOYSA-N 3-amino-4-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2-[(2-methylpropan-2-yl)oxy]benzoic acid Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=C(OC(C)(C)C)C(C(O)=O)=CC=2)N)=C1 RMFKWWDNIKWLNN-UHFFFAOYSA-N 0.000 description 2
NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 2
KKFQIFLHVDGQIW-UHFFFAOYSA-N 3-cyano-n-[(2-methylpropan-2-yl)oxy]benzamide Chemical compound CC(C)(C)ONC(=O)C1=CC=CC(C#N)=C1 KKFQIFLHVDGQIW-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
HSZLBBZSPHXHDJ-UHFFFAOYSA-N 4-[(4-amino-5-cyano-1,3-thiazol-2-yl)amino]benzenesulfonamide Chemical compound S1C(C#N)=C(N)N=C1NC1=CC=C(S(N)(=O)=O)C=C1 HSZLBBZSPHXHDJ-UHFFFAOYSA-N 0.000 description 2
WSVCIWJKLYVDLA-UHFFFAOYSA-N 4-amino-2-(4-propan-2-ylanilino)-1,3-thiazole-5-carbothioamide Chemical compound C1=CC(C(C)C)=CC=C1NC1=NC(N)=C(C(N)=S)S1 WSVCIWJKLYVDLA-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
OMNHTTWQSSUZHO-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=C1O OMNHTTWQSSUZHO-UHFFFAOYSA-N 0.000 description 2
GGVQPLOEDLGZCX-UHFFFAOYSA-N 5-[3-(3-aminophenyl)-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(N)C=CC=2)=C1 GGVQPLOEDLGZCX-UHFFFAOYSA-N 0.000 description 2
XRTUGPXTPHQKFN-UHFFFAOYSA-N 5-[6-(furan-2-yl)pyridin-2-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C(C=CC=2)C=2OC=CC=2)=C1 XRTUGPXTPHQKFN-UHFFFAOYSA-N 0.000 description 2
QZLSBOVWPHXCLT-UHFFFAOYSA-N 5-chlorothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)S1 QZLSBOVWPHXCLT-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
102100034594 Angiopoietin-1 Human genes 0.000 description 2
108010048154 Angiopoietin-1 Proteins 0.000 description 2
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
102000002427 Cyclin B Human genes 0.000 description 2
108010068150 Cyclin B Proteins 0.000 description 2
102000003909 Cyclin E Human genes 0.000 description 2
108090000257 Cyclin E Proteins 0.000 description 2
108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 2
101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 2
102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
108091008794 FGF receptors Proteins 0.000 description 2
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
230000010337 G2 phase Effects 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101000715942 Homo sapiens Cyclin-dependent kinase 4 Proteins 0.000 description 2
101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
229910021380 Manganese Chloride Inorganic materials 0.000 description 2
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
101100481410 Mus musculus Tek gene Proteins 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
229910006074 SO2NH2 Inorganic materials 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
229910021626 Tin(II) chloride Chemical group 0.000 description 2
102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
206010064930 age-related macular degeneration Diseases 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
238000003782 apoptosis assay Methods 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
229910052681 coesite Inorganic materials 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
229910052906 cristobalite Inorganic materials 0.000 description 2
239000012043 crude product Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
238000007429 general method Methods 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
102000048992 human CDK4 Human genes 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000002329 infrared spectrum Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
229940043355 kinase inhibitor Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000011565 manganese chloride Substances 0.000 description 2
235000002867 manganese chloride Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
230000037361 pathway Effects 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
230000005522 programmed cell death Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000022983 regulation of cell cycle Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000001119 stannous chloride Chemical group 0.000 description 2
235000011150 stannous chloride Nutrition 0.000 description 2
229910052682 stishovite Inorganic materials 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
108010065665 syntide-2 Proteins 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
239000012085 test solution Substances 0.000 description 2
KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
229910052905 tridymite Inorganic materials 0.000 description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
239000013598 vector Substances 0.000 description 2
239000008096 xylene Substances 0.000 description 2
239000011592 zinc chloride Substances 0.000 description 2
235000005074 zinc chloride Nutrition 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
NKBRRWBNPNUBDD-TYKVATLISA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[2-[[(2s)-1-[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-4-methyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]pentanoyl]amino]-3 Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)[C@@H](C)O)C(=O)[C@@H]1CCCN1 NKBRRWBNPNUBDD-TYKVATLISA-N 0.000 description 1
JAOXYZVWRQDPGB-UHFFFAOYSA-N (4-sulfamoylphenyl) thiocyanate Chemical compound NS(=O)(=O)C1=CC=C(SC#N)C=C1 JAOXYZVWRQDPGB-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical compound BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 1
QHHHLHCCVDMOJI-UHFFFAOYSA-N 1,3-thiazol-4-amine Chemical class NC1=CSC=N1 QHHHLHCCVDMOJI-UHFFFAOYSA-N 0.000 description 1
WKXCZMFWXZRMEZ-UHFFFAOYSA-N 1,3-thiazole-2,4-diamine Chemical class NC1=CSC(N)=N1 WKXCZMFWXZRMEZ-UHFFFAOYSA-N 0.000 description 1
CGXJUBDTCAAXAY-UHFFFAOYSA-N 1-(3-aminophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=CC(N)=C1 CGXJUBDTCAAXAY-UHFFFAOYSA-N 0.000 description 1
HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
SPMLMLQATWNZEE-UHFFFAOYSA-N 2-(chloromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(CCl)=NC2=C1 SPMLMLQATWNZEE-UHFFFAOYSA-N 0.000 description 1
BWCCPOQIMGGGQX-UHFFFAOYSA-N 2-(chloromethyl)-4,6-dimethoxypyrimidine Chemical compound COC1=CC(OC)=NC(CCl)=N1 BWCCPOQIMGGGQX-UHFFFAOYSA-N 0.000 description 1
AJKIAERFLWQLAM-UHFFFAOYSA-N 2-(chloromethyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole Chemical compound O1C(CCl)=NN=C1C1=CC=C(Cl)C=C1 AJKIAERFLWQLAM-UHFFFAOYSA-N 0.000 description 1
WZEWEZMUYDNMCZ-UHFFFAOYSA-N 2-(chloromethyl)-6-methoxy-1h-benzimidazole Chemical compound COC1=CC=C2N=C(CCl)NC2=C1 WZEWEZMUYDNMCZ-UHFFFAOYSA-N 0.000 description 1
NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
DDEAEWMDOSXKBX-UHFFFAOYSA-N 2-(chloromethyl)quinoline Chemical compound C1=CC=CC2=NC(CCl)=CC=C21 DDEAEWMDOSXKBX-UHFFFAOYSA-N 0.000 description 1
MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
ASEWVBHXCVYGCB-UHFFFAOYSA-N 2-[4-amino-2-[4-(dimethylamino)anilino]-1,3-thiazol-5-yl]-5-(2-hydroxyphenyl)-1,3-thiazol-4-ol Chemical compound C1=CC(N(C)C)=CC=C1NC1=NC(N)=C(C=2SC(=C(O)N=2)C=2C(=CC=CC=2)O)S1 ASEWVBHXCVYGCB-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
QCXCIYPOMMIBHO-UHFFFAOYSA-N 2-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)S1 QCXCIYPOMMIBHO-UHFFFAOYSA-N 0.000 description 1
MFFNMGRQCGWICP-UHFFFAOYSA-N 2-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-pyridin-2-yl-1,3-thiazole-2,4-diamine Chemical compound NC=1N=C(NC=2C=C3OCCOC3=CC=2)SC=1C1=CC=CC=N1 MFFNMGRQCGWICP-UHFFFAOYSA-N 0.000 description 1
XGSDDKQRGTWANC-UHFFFAOYSA-N 2-n-(3,4-dimethoxyphenyl)-5-pyridin-2-yl-1,3-thiazole-2,4-diamine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC(N)=C(C=2N=CC=CC=2)S1 XGSDDKQRGTWANC-UHFFFAOYSA-N 0.000 description 1
GCKYUSVGXDHLIA-UHFFFAOYSA-N 2-n-[4-(dimethylamino)phenyl]-5-(2h-tetrazol-5-yl)-1,3-thiazole-2,4-diamine Chemical compound C1=CC(N(C)C)=CC=C1NC1=NC(N)=C(C2=NNN=N2)S1 GCKYUSVGXDHLIA-UHFFFAOYSA-N 0.000 description 1
FJNLCHNQVJVCPY-UHFFFAOYSA-N 2-n-methoxy-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OC)=N1 FJNLCHNQVJVCPY-UHFFFAOYSA-N 0.000 description 1
GILCFOZQOQMDFK-UHFFFAOYSA-N 2-n-phenyl-5-pyridin-2-yl-1,3-thiazole-2,4-diamine Chemical compound S1C(C=2N=CC=CC=2)=C(N)N=C1NC1=CC=CC=C1 GILCFOZQOQMDFK-UHFFFAOYSA-N 0.000 description 1
MAGGXASHVAMJCT-UHFFFAOYSA-N 3-(bromomethyl)-6,7-dimethoxy-1-methylquinoxalin-2-one Chemical compound N1=C(CBr)C(=O)N(C)C2=C1C=C(OC)C(OC)=C2 MAGGXASHVAMJCT-UHFFFAOYSA-N 0.000 description 1
VJKQKVCFLMLRJX-UHFFFAOYSA-N 3-(chloromethyl)-1-(3,5-dichlorophenyl)-5-methylpyrazole Chemical compound CC1=CC(CCl)=NN1C1=CC(Cl)=CC(Cl)=C1 VJKQKVCFLMLRJX-UHFFFAOYSA-N 0.000 description 1
UBNGKQCKUVRCGR-UHFFFAOYSA-N 3-(chloromethyl)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NOC(C)=C1C1=NC(CCl)=NO1 UBNGKQCKUVRCGR-UHFFFAOYSA-N 0.000 description 1
RSSBMWQNIDHJNS-UHFFFAOYSA-N 3-(chloromethyl)-5-(thiadiazol-4-yl)-1,2,4-oxadiazole Chemical compound ClCC1=NOC(C=2N=NSC=2)=N1 RSSBMWQNIDHJNS-UHFFFAOYSA-N 0.000 description 1
FEXTXBAFBURKGS-UHFFFAOYSA-N 3-(chloromethyl)-5-methyl-1,2-oxazole Chemical compound CC1=CC(CCl)=NO1 FEXTXBAFBURKGS-UHFFFAOYSA-N 0.000 description 1
KHJYOJVUQYWASE-UHFFFAOYSA-N 3-(chloromethyl)-5-thiophen-3-yl-1,2,4-oxadiazole Chemical compound ClCC1=NOC(C2=CSC=C2)=N1 KHJYOJVUQYWASE-UHFFFAOYSA-N 0.000 description 1
FKXUTRIRDQHANY-UHFFFAOYSA-N 3-amino-4-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2-phenylmethoxybenzoic acid Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=C(OCC=3C=CC=CC=3)C(C(O)=O)=CC=2)N)=C1 FKXUTRIRDQHANY-UHFFFAOYSA-N 0.000 description 1
PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
NUSXEDNPFNWFDQ-UHFFFAOYSA-N 3-chloro-2-(chloromethyl)-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CN=C(CCl)C(Cl)=C1 NUSXEDNPFNWFDQ-UHFFFAOYSA-N 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
PUZFMDAJRJLNJN-UHFFFAOYSA-N 3-methyloctanamide Chemical compound CCCCCC(C)CC(N)=O PUZFMDAJRJLNJN-UHFFFAOYSA-N 0.000 description 1
UEJQTBKTWJQBRN-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-chlorophenyl)-1,3-thiazole Chemical compound ClCC1=CSC(C=2C=CC(Cl)=CC=2)=N1 UEJQTBKTWJQBRN-UHFFFAOYSA-N 0.000 description 1
VCTKYTBWZTZPHF-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-2-phenyl-1,3-oxazole Chemical compound ClCC1=C(C)OC(C=2C=CC=CC=2)=N1 VCTKYTBWZTZPHF-UHFFFAOYSA-N 0.000 description 1
AXVSFLPKWJREOR-UHFFFAOYSA-N 4-[2-amino-3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-5-methyl-1,3-thiazole-2-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=C(C3=C(SC(=N3)C(O)=O)C)C=CC=2)N)=C1 AXVSFLPKWJREOR-UHFFFAOYSA-N 0.000 description 1
JOYLNPOUQUOJQV-UHFFFAOYSA-N 4-[[4-amino-5-(5-nitro-1,3-benzothiazol-2-yl)-1,3-thiazol-2-yl]amino]benzenesulfonamide Chemical compound S1C(C=2SC3=CC=C(C=C3N=2)[N+]([O-])=O)=C(N)N=C1NC1=CC=C(S(N)(=O)=O)C=C1 JOYLNPOUQUOJQV-UHFFFAOYSA-N 0.000 description 1
QHMNGBYYFZHHIT-UHFFFAOYSA-N 4-[[4-amino-5-[1-[(4-chlorophenyl)methyl]imidazol-2-yl]-1,3-thiazol-2-yl]amino]benzenesulfonamide Chemical compound S1C(C=2N(C=CN=2)CC=2C=CC(Cl)=CC=2)=C(N)N=C1NC1=CC=C(S(N)(=O)=O)C=C1 QHMNGBYYFZHHIT-UHFFFAOYSA-N 0.000 description 1
XPXLWEBNQPZCBC-UHFFFAOYSA-N 4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazole-5-carbonitrile Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C#N)=C1 XPXLWEBNQPZCBC-UHFFFAOYSA-N 0.000 description 1
NYEMVPGQXLAKEH-UHFFFAOYSA-N 4-amino-2-(4-sulfamoylanilino)-1,3-thiazole-5-carboxamide Chemical compound NC1=C(C(=O)N)SC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 NYEMVPGQXLAKEH-UHFFFAOYSA-N 0.000 description 1
NNMYRMGMVLMQAY-UHFFFAOYSA-N 4-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=N1 NNMYRMGMVLMQAY-UHFFFAOYSA-N 0.000 description 1
SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical class OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
MIZXPOWOTSPACV-UHFFFAOYSA-N 5-(5-thiophen-3-yl-1,2,4-oxadiazol-3-yl)-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C(ON=2)C2=CSC=C2)=C1 MIZXPOWOTSPACV-UHFFFAOYSA-N 0.000 description 1
DDLQRIDMGNVKCJ-UHFFFAOYSA-N 5-(6-thiophen-2-ylpyridin-2-yl)-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C(C=CC=2)C=2SC=CC=2)=C1 DDLQRIDMGNVKCJ-UHFFFAOYSA-N 0.000 description 1
NAGJNOJBNXYWAP-UHFFFAOYSA-N 5-(6-thiophen-3-ylpyridin-2-yl)-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C(C=CC=2)C2=CSC=C2)=C1 NAGJNOJBNXYWAP-UHFFFAOYSA-N 0.000 description 1
BJVYSQGEJHKTBW-UHFFFAOYSA-N 5-(chloromethyl)-3-(4-chlorophenyl)-1,2,4-oxadiazole Chemical compound O1C(CCl)=NC(C=2C=CC(Cl)=CC=2)=N1 BJVYSQGEJHKTBW-UHFFFAOYSA-N 0.000 description 1
RYZHGEZWUMHELK-UHFFFAOYSA-N 5-(chloromethyl)-3-(4-chlorophenyl)-1h-1,2,4-triazole Chemical compound N1C(CCl)=NN=C1C1=CC=C(Cl)C=C1 RYZHGEZWUMHELK-UHFFFAOYSA-N 0.000 description 1
MFEGTJBBLPXXDT-UHFFFAOYSA-N 5-(chloromethyl)-3-(pyridin-2-ylsulfonylmethyl)-1,2,4-oxadiazole Chemical compound O1C(CCl)=NC(CS(=O)(=O)C=2N=CC=CC=2)=N1 MFEGTJBBLPXXDT-UHFFFAOYSA-N 0.000 description 1
WNGOJBWAZODOJP-OAHLLOKOSA-N 5-[(4r)-4-benzyl-4,5-dihydro-1,3-oxazol-2-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2OC[C@@H](CC=3C=CC=CC=3)N=2)=C1 WNGOJBWAZODOJP-OAHLLOKOSA-N 0.000 description 1
KVFQFCXDQVNXDP-AWEZNQCLSA-N 5-[(4r)-4-phenyl-4,5-dihydro-1,3-oxazol-2-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2OC[C@H](N=2)C=2C=CC=CC=2)=C1 KVFQFCXDQVNXDP-AWEZNQCLSA-N 0.000 description 1
YVFDOWOSUGHFLZ-SJKOYZFVSA-N 5-[(4r,5s)-4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2O[C@H]([C@@H](C)N=2)C=2C=CC=CC=2)=C1 YVFDOWOSUGHFLZ-SJKOYZFVSA-N 0.000 description 1
GTKJJEACWZVULL-UHFFFAOYSA-N 5-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=CC(=CC=2)C(C)(C)C)=C1 GTKJJEACWZVULL-UHFFFAOYSA-N 0.000 description 1
JQCXZWGGVZLEOP-UHFFFAOYSA-N 5-[3-(5-amino-2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC(F)=C(N)C=2)Cl)=C1 JQCXZWGGVZLEOP-UHFFFAOYSA-N 0.000 description 1
UFQHDYLQSUOOPZ-UHFFFAOYSA-N 5-[3-(5-amino-2-chlorophenyl)-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC=C(N)C=2)Cl)=C1 UFQHDYLQSUOOPZ-UHFFFAOYSA-N 0.000 description 1
MWUVKOQSEMZSMN-UHFFFAOYSA-N 5-[3-(5-amino-2-fluoro-4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound C1=C(N)C(OC)=CC(F)=C1C1=NOC(C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=N1 MWUVKOQSEMZSMN-UHFFFAOYSA-N 0.000 description 1
ACTOSDMFRAMWLE-UHFFFAOYSA-N 5-[3-(5-amino-2-methylphenyl)-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC=C(N)C=2)C)=C1 ACTOSDMFRAMWLE-UHFFFAOYSA-N 0.000 description 1
VAHMGEKROQCCCS-UHFFFAOYSA-N 5-[3-[3-(5-propan-2-yl-1h-1,2,4-triazol-3-yl)phenyl]-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(C=CC=2)C=2NN=C(N=2)C(C)C)=C1 VAHMGEKROQCCCS-UHFFFAOYSA-N 0.000 description 1
JHQONXHAPLRSTD-UHFFFAOYSA-N 5-[3-[3-(methoxymethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COCOC1=CC=CC(C=2N=C(ON=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 JHQONXHAPLRSTD-UHFFFAOYSA-N 0.000 description 1
KJFGXEAWTFOJJQ-UHFFFAOYSA-N 5-[4-(chloromethyl)-1,3-thiazol-2-yl]-1,2-oxazole Chemical compound ClCC1=CSC(C=2ON=CC=2)=N1 KJFGXEAWTFOJJQ-UHFFFAOYSA-N 0.000 description 1
YVTQHZDUDUCGRD-UHFFFAOYSA-N 5-bromofuran-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)O1 YVTQHZDUDUCGRD-UHFFFAOYSA-N 0.000 description 1
COWZPSUDTMGBAT-UHFFFAOYSA-N 5-bromothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)S1 COWZPSUDTMGBAT-UHFFFAOYSA-N 0.000 description 1
FFFMIFUBJZBTCG-UHFFFAOYSA-N 5-chloro-3-(chloromethyl)-1,2,4-thiadiazole Chemical compound ClCC1=NSC(Cl)=N1 FFFMIFUBJZBTCG-UHFFFAOYSA-N 0.000 description 1
DADXWROZAWLOFB-UHFFFAOYSA-N 5-chloro-4-(chloromethyl)thiadiazole Chemical compound ClCC=1N=NSC=1Cl DADXWROZAWLOFB-UHFFFAOYSA-N 0.000 description 1
AFWKAIYTSPWWCA-UHFFFAOYSA-N 5-isothiocyanato-1,2,3-trimethoxybenzene Chemical compound COC1=CC(N=C=S)=CC(OC)=C1OC AFWKAIYTSPWWCA-UHFFFAOYSA-N 0.000 description 1
UYDGNRLMYZMDOG-UHFFFAOYSA-N 5-methyl-1,3-thiazole-2-carboxylic acid Chemical compound CC1=CN=C(C(O)=O)S1 UYDGNRLMYZMDOG-UHFFFAOYSA-N 0.000 description 1
VCNGNQLPFHVODE-UHFFFAOYSA-N 5-methylthiophene-2-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)S1 VCNGNQLPFHVODE-UHFFFAOYSA-N 0.000 description 1
RUKDIKJSGDVSIF-UHFFFAOYSA-N 5-phenyl-1,3-oxazole-4-carboxylic acid Chemical compound N1=COC(C=2C=CC=CC=2)=C1C(=O)O RUKDIKJSGDVSIF-UHFFFAOYSA-N 0.000 description 1
FPSIJTQWAZLSIH-UHFFFAOYSA-N 5-pyridin-2-yl-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=CC=CC=2)=C1 FPSIJTQWAZLSIH-UHFFFAOYSA-N 0.000 description 1
BXANGIZBUPAFHR-UHFFFAOYSA-N 5-quinolin-2-yl-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C3C=CC=CC3=CC=2)=C1 BXANGIZBUPAFHR-UHFFFAOYSA-N 0.000 description 1
AIVSLDAXUIRICJ-UHFFFAOYSA-N 5-tert-butyl-3-(chloromethyl)-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NC(CCl)=NO1 AIVSLDAXUIRICJ-UHFFFAOYSA-N 0.000 description 1
ZKCAVUYFKJKMRI-UHFFFAOYSA-N 6-(chloromethyl)-2-propan-2-yl-1h-pyrimidin-4-one Chemical compound CC(C)C1=NC(=O)C=C(CCl)N1 ZKCAVUYFKJKMRI-UHFFFAOYSA-N 0.000 description 1
ZLKMOIHCHCMSFW-UHFFFAOYSA-N 6-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Cl)=N1 ZLKMOIHCHCMSFW-UHFFFAOYSA-N 0.000 description 1
DABLXYJWGJFYIK-UHFFFAOYSA-N 7-[(4-bromophenyl)-(8-hydroxy-6-oxo-3,4-dihydro-2H-pyrimido[2,1-b][1,3]thiazin-7-yl)methyl]-8-hydroxy-3,4-dihydro-2H-pyrimido[2,1-b][1,3]thiazin-6-one Chemical compound [O-]c1[nH+]c2SCCCn2c(=O)c1C(c1ccc(Br)cc1)c1c([O-])[nH+]c2SCCCn2c1=O DABLXYJWGJFYIK-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102100034608 Angiopoietin-2 Human genes 0.000 description 1
108010048036 Angiopoietin-2 Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
101150012716 CDK1 gene Proteins 0.000 description 1
101150095530 CDS1 gene Proteins 0.000 description 1
101150050673 CHK1 gene Proteins 0.000 description 1
LFEFATYYLOGTCQ-HDJSIYSDSA-N COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)N[C@@H]4CC[C@@H](O)CC4)S3)N)C=2)F)=C1 Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)N[C@@H]4CC[C@@H](O)CC4)S3)N)C=2)F)=C1 LFEFATYYLOGTCQ-HDJSIYSDSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
108010060385 Cyclin B1 Proteins 0.000 description 1
108010060387 Cyclin B2 Proteins 0.000 description 1
102000003910 Cyclin D Human genes 0.000 description 1
108090000259 Cyclin D Proteins 0.000 description 1
108010058544 Cyclin D2 Proteins 0.000 description 1
108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
239000012623 DNA damaging agent Substances 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
101000953655 Danio rerio Vascular endothelial growth factor receptor kdr-like Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
101150021185 FGF gene Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
230000037060 G2 phase arrest Effects 0.000 description 1
102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
102100033201 G2/mitotic-specific cyclin-B2 Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000031448 Genomic Instability Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000007821 HATU Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 1
101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
206010058490 Hyperoxia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 1
229910017912 NH2OH Inorganic materials 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical class COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
NHJSWORVNIOXIT-UHFFFAOYSA-N PD-166866 Chemical compound COC1=CC(OC)=CC(C=2C(=NC3=NC(N)=NC=C3C=2)NC(=O)NC(C)(C)C)=C1 NHJSWORVNIOXIT-UHFFFAOYSA-N 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
206010038933 Retinopathy of prematurity Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
YZVSGSJXPAJXOW-UHFFFAOYSA-N [3-[5-(2,4-diamino-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]carbamic acid Chemical compound S1C(N)=NC(N)=C1C1=NC(C=2C=C(NC(O)=O)C=CC=2)=NO1 YZVSGSJXPAJXOW-UHFFFAOYSA-N 0.000 description 1
LAJYPBBEOOFMQD-UHFFFAOYSA-N [3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-fluorophenyl]-[(2-methylpropan-2-yl)oxy]carbamic acid Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC=C(C=2)N(OC(C)(C)C)C(O)=O)F)=C1 LAJYPBBEOOFMQD-UHFFFAOYSA-N 0.000 description 1
MYISTVMWZSRGAV-UHFFFAOYSA-N [3-[5-[4-amino-2-(tritylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]carbamic acid Chemical compound S1C(C=2ON=C(N=2)C=2C=C(NC(O)=O)C=CC=2)=C(N)N=C1NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 MYISTVMWZSRGAV-UHFFFAOYSA-N 0.000 description 1
ZPZHAUXTGFNYTN-UHFFFAOYSA-N [isothiocyanato(diphenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N=C=S)C1=CC=CC=C1 ZPZHAUXTGFNYTN-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
MANVMTSCCSAYSN-UHFFFAOYSA-N acetonitrile;2-methylpropan-2-ol Chemical compound CC#N.CC(C)(C)O MANVMTSCCSAYSN-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
229940061720 alpha hydroxy acid Drugs 0.000 description 1
150000001280 alpha hydroxy acids Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000015624 blood vessel development Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
150000001649 bromium compounds Chemical class 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
125000005534 decanoate group Chemical class 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000002074 deregulated effect Effects 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
WORJEOGGNQDSOE-FNLFVDAESA-N deuteriooxymethane trichloro(deuterio)methane Chemical compound [2H]OC.[2H]C(Cl)(Cl)Cl WORJEOGGNQDSOE-FNLFVDAESA-N 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000002224 dissection Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
201000005619 esophageal carcinoma Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
201000000497 familial melanoma Diseases 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229960001867 guaiacol Drugs 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
239000003668 hormone analog Substances 0.000 description 1
102000048620 human CHEK1 Human genes 0.000 description 1
102000055590 human KDR Human genes 0.000 description 1
102000057090 human PTK2 Human genes 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
229960004337 hydroquinone Drugs 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000000222 hyperoxic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000016507 interphase Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
150000004694 iodide salts Chemical class 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229940047889 isobutyramide Drugs 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
150000002690 malonic acid derivatives Chemical class 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
125000005905 mesyloxy group Chemical group 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
230000035772 mutation Effects 0.000 description 1
DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
JMJUHQGPXJPKRH-UHFFFAOYSA-N n-[3-(2-bromoacetyl)phenyl]-5-chlorothiophene-2-carboxamide Chemical compound S1C(Cl)=CC=C1C(=O)NC1=CC=CC(C(=O)CBr)=C1 JMJUHQGPXJPKRH-UHFFFAOYSA-N 0.000 description 1
YTSCJNGLTOKOEQ-UHFFFAOYSA-N n-[3-(2-bromoacetyl)phenyl]benzamide Chemical compound BrCC(=O)C1=CC=CC(NC(=O)C=2C=CC=CC=2)=C1 YTSCJNGLTOKOEQ-UHFFFAOYSA-N 0.000 description 1
FZFIYOAPPGZOJL-UHFFFAOYSA-N n-[3-[2-(2,4-diamino-1,3-thiazol-5-yl)-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound S1C(N)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=CS1 FZFIYOAPPGZOJL-UHFFFAOYSA-N 0.000 description 1
RRAJZEHDJJVEPL-UHFFFAOYSA-N n-[3-[5-(2-acetamido-4-amino-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]-3-chlorobenzamide Chemical compound S1C(NC(=O)C)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(Cl)C=CC=3)C=CC=2)=NO1 RRAJZEHDJJVEPL-UHFFFAOYSA-N 0.000 description 1
WNMGYLGYARZGMV-UHFFFAOYSA-N n-[3-[5-(4-amino-2-benzamido-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]-3-chlorobenzamide Chemical compound S1C(C=2ON=C(N=2)C=2C=C(NC(=O)C=3C=C(Cl)C=CC=3)C=CC=2)=C(N)N=C1NC(=O)C1=CC=CC=C1 WNMGYLGYARZGMV-UHFFFAOYSA-N 0.000 description 1
RGSPNONQAYJXTR-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-fluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C(F)=CC=2)C=2N=C(ON=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 RGSPNONQAYJXTR-UHFFFAOYSA-N 0.000 description 1
VKKSZZSMQVWXNM-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-methylphenyl]-3-chlorobenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC=C(NC(=O)C=3C=C(Cl)C=CC=3)C=2)C)=C1 VKKSZZSMQVWXNM-UHFFFAOYSA-N 0.000 description 1
RZOCTZOINVDOFN-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C(C)=CC=2)C=2N=C(ON=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 RZOCTZOINVDOFN-UHFFFAOYSA-N 0.000 description 1
LTBGJAKKIKOHSV-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3,5-dimethylbenzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(NC(=O)C=3C=C(C)C=C(C)C=3)C=CC=2)=C1 LTBGJAKKIKOHSV-UHFFFAOYSA-N 0.000 description 1
SJHRSDQWFAOIAJ-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-(trifluoromethyl)benzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=CC=2)=C1 SJHRSDQWFAOIAJ-UHFFFAOYSA-N 0.000 description 1
KQPZNBADPKSMEB-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-chlorobenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(NC(=O)C=3C=C(Cl)C=CC=3)C=CC=2)=C1 KQPZNBADPKSMEB-UHFFFAOYSA-N 0.000 description 1
IVTFNEMGDKZBCE-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(ON=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 IVTFNEMGDKZBCE-UHFFFAOYSA-N 0.000 description 1
RNUZZENUQQQZDZ-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(NC(=O)C=3C=C(C)C=CC=3)C=CC=2)=C1 RNUZZENUQQQZDZ-UHFFFAOYSA-N 0.000 description 1
LVVKMLFIYNWNIG-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]acetamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(NC(C)=O)C=CC=2)=C1 LVVKMLFIYNWNIG-UHFFFAOYSA-N 0.000 description 1
QPGOMHQCTKAMIS-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=C1 QPGOMHQCTKAMIS-UHFFFAOYSA-N 0.000 description 1
HUSJGCHDRGJUGH-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3-amino-6-morpholin-4-ylpyridin-2-yl)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C(C)=CC=2)C=2N=C(ON=2)C2=C(N=C(S2)C=2C(=CC=C(N=2)N2CCOCC2)N)N)=C1 HUSJGCHDRGJUGH-UHFFFAOYSA-N 0.000 description 1
QRYVSMRZLRTCBB-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3-aminopyridin-2-yl)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-chlorobenzamide Chemical compound NC=1N=C(C=2C(=CC=CN=2)N)SC=1C(ON=1)=NC=1C(C=1)=CC=CC=1NC(=O)C1=CC=CC(Cl)=C1 QRYVSMRZLRTCBB-UHFFFAOYSA-N 0.000 description 1
IABQUQFYGOHZOQ-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3-morpholin-4-ylpropylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(ON=2)C2=C(N=C(NC(=O)NCCCN3CCOCC3)S2)N)=C1 IABQUQFYGOHZOQ-UHFFFAOYSA-N 0.000 description 1
UAOAQVDRWJESEB-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(benzylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(ON=2)C2=C(N=C(NC(=O)NCC=3C=CC=CC=3)S2)N)=C1 UAOAQVDRWJESEB-UHFFFAOYSA-N 0.000 description 1
OTVMTTXWIFYVMO-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(methanesulfonamido)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(ON=2)C2=C(N=C(NS(C)(=O)=O)S2)N)=C1 OTVMTTXWIFYVMO-UHFFFAOYSA-N 0.000 description 1
MGFZFZRURLWOFI-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(methylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound S1C(NC(=O)NC)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(C)C=CC=3)C=CC=2)=NO1 MGFZFZRURLWOFI-UHFFFAOYSA-N 0.000 description 1
IGSZJONBMJNESL-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(phenylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(ON=2)C2=C(N=C(NC(=O)NC=3C=CC=CC=3)S2)N)=C1 IGSZJONBMJNESL-UHFFFAOYSA-N 0.000 description 1
FNOSXKUFNBHRNB-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(propan-2-ylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound S1C(NC(=O)NC(C)C)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(C)C=CC=3)C=CC=2)=NO1 FNOSXKUFNBHRNB-UHFFFAOYSA-N 0.000 description 1
VJPGSGFDJPHBMZ-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(propanoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-chlorobenzamide Chemical compound S1C(NC(=O)CC)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(Cl)C=CC=3)C=CC=2)=NO1 VJPGSGFDJPHBMZ-UHFFFAOYSA-N 0.000 description 1
NBUKMHXINQOFDI-UHFFFAOYSA-N n-[4-(chloromethyl)-1,3-thiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC(CCl)=CS1 NBUKMHXINQOFDI-UHFFFAOYSA-N 0.000 description 1
MKIDEHRKLAONRP-UHFFFAOYSA-N n-[5-[5-(2,4-diamino-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(N)S3)N)C=2)F)=C1 MKIDEHRKLAONRP-UHFFFAOYSA-N 0.000 description 1
JVVGVWZXAYITBX-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(2-hydroxyethylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCCO)S3)N)C=2)F)=C1 JVVGVWZXAYITBX-UHFFFAOYSA-N 0.000 description 1
DEPLPDUTJUFQJP-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(2-methylpropylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCC(C)C)S3)N)C=2)F)=C1 DEPLPDUTJUFQJP-UHFFFAOYSA-N 0.000 description 1
GVQCMQZGPFPMNM-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(2-morpholin-4-ylethylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCCN4CCOCC4)S3)N)C=2)F)=C1 GVQCMQZGPFPMNM-UHFFFAOYSA-N 0.000 description 1
KAWXMUIAAFAASH-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-chlorobenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC(F)=C(NC(=O)C=3C=C(Cl)C=CC=3)C=2)F)=C1 KAWXMUIAAFAASH-UHFFFAOYSA-N 0.000 description 1
HAPMXNDWLJTRSV-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-chloro-2-fluorophenyl]-3-chlorobenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC(F)=C(NC(=O)C=3C=C(Cl)C=CC=3)C=2)Cl)=C1 HAPMXNDWLJTRSV-UHFFFAOYSA-N 0.000 description 1
YWVOMTCJWLFMEX-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-chloro-2-fluorophenyl]-3-methoxybenzamide Chemical class COC1=CC=CC(C(=O)NC=2C(=CC(Cl)=C(C=3N=C(ON=3)C3=C(N=C(NC=4C=C(OC)C(OC)=C(OC)C=4)S3)N)C=2)F)=C1 YWVOMTCJWLFMEX-UHFFFAOYSA-N 0.000 description 1
GMCWEKMPBDFQHH-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(methylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound S1C(NC(=O)NC)=NC(N)=C1C1=NC(C=2C(=CC(F)=C(NC(=O)C=3C=C(OC)C=CC=3)C=2)F)=NO1 GMCWEKMPBDFQHH-UHFFFAOYSA-N 0.000 description 1
QNOSFBYTDFISMM-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(oxolan-2-ylmethylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCC4OCCC4)S3)N)C=2)F)=C1 QNOSFBYTDFISMM-UHFFFAOYSA-N 0.000 description 1
GTVMEAWUBBAPTB-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(propan-2-ylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(C)C)S3)N)C=2)F)=C1 GTVMEAWUBBAPTB-UHFFFAOYSA-N 0.000 description 1
UEFCIEORXJADHB-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(pyridin-2-ylmethylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCC=4N=CC=CC=4)S3)N)C=2)F)=C1 UEFCIEORXJADHB-UHFFFAOYSA-N 0.000 description 1
PMVLQNJNYQIXKC-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(pyridin-3-ylmethylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCC=4C=NC=CC=4)S3)N)C=2)F)=C1 PMVLQNJNYQIXKC-UHFFFAOYSA-N 0.000 description 1
CJSQMWJIXUBAGG-UHFFFAOYSA-N n-[5-[5-[4-amino-2-[(2-amino-2-oxoethyl)carbamoylamino]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCC(N)=O)S3)N)C=2)F)=C1 CJSQMWJIXUBAGG-UHFFFAOYSA-N 0.000 description 1
ODXRYPZBKZJPMC-UHFFFAOYSA-N n-[5-[5-[4-amino-2-[(6-morpholin-4-ylpyridin-3-yl)amino]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC=4C=NC(=CC=4)N4CCOCC4)S3)N)C=2)F)=C1 ODXRYPZBKZJPMC-UHFFFAOYSA-N 0.000 description 1
PVRVVWDMIMCHHM-UHFFFAOYSA-N n-[5-[5-[4-amino-2-[2-(2-hydroxyethoxy)ethylcarbamoylamino]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCCOCCO)S3)N)C=2)F)=C1 PVRVVWDMIMCHHM-UHFFFAOYSA-N 0.000 description 1
AXJNCDNJBHOEFK-UHFFFAOYSA-N n-[5-[5-[4-amino-2-[3-(2-oxopyrrolidin-1-yl)propylcarbamoylamino]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCCCN4C(CCC4)=O)S3)N)C=2)F)=C1 AXJNCDNJBHOEFK-UHFFFAOYSA-N 0.000 description 1
FWVXNVVNMDZAMY-UHFFFAOYSA-N n-[5-[5-[4-amino-2-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2-chloro-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(C)=C(C=3N=C(ON=3)C3=C(N=C(S3)C=3C=NC(=CC=3)N3CCN(C)CC3)N)C=2)Cl)=C1 FWVXNVVNMDZAMY-UHFFFAOYSA-N 0.000 description 1
XWCCTMBMQUCLSI-UHFFFAOYSA-N n-ethyl-n-propylpropan-1-amine Chemical compound CCCN(CC)CCC XWCCTMBMQUCLSI-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940116315 oxalic acid Drugs 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
XAFJSPPHVXDRIE-UHFFFAOYSA-L platinum(2+);triphenylphosphane;dichloride Chemical compound [Cl-].[Cl-].[Pt+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 XAFJSPPHVXDRIE-UHFFFAOYSA-L 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
230000035409 positive regulation of cell proliferation Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940080818 propionamide Drugs 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical class C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 description 1
DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
239000012925 reference material Substances 0.000 description 1
230000026267 regulation of growth Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
229960001755 resorcinol Drugs 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000005185 salting out Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
229960000414 sodium fluoride Drugs 0.000 description 1
239000008279 sol Substances 0.000 description 1
238000003797 solvolysis reaction Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
125000005504 styryl group Chemical group 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
SVYUQSKDJNCYFF-UHFFFAOYSA-N tert-butyl n-[3-[5-(4-amino-2-phenyl-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]-4-methylphenyl]carbamate Chemical compound CC1=CC=C(NC(=O)OC(C)(C)C)C=C1C1=NOC(C2=C(N=C(S2)C=2C=CC=CC=2)N)=N1 SVYUQSKDJNCYFF-UHFFFAOYSA-N 0.000 description 1
KBZZJFNFBRJDPN-UHFFFAOYSA-N tert-butyl n-[5-[5-[4-amino-2-(propan-2-ylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]carbamate Chemical compound S1C(NC(C)C)=NC(N)=C1C1=NC(C=2C(=CC(F)=C(NC(=O)OC(C)(C)C)C=2)F)=NO1 KBZZJFNFBRJDPN-UHFFFAOYSA-N 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
125000005306 thianaphthenyl group Chemical group 0.000 description 1
150000007979 thiazole derivatives Chemical class 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000036964 tight binding Effects 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000016596 traversing start control point of mitotic cell cycle Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000006459 vascular development Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
GDJZZWYLFXAGFH-UHFFFAOYSA-M xylenesulfonate group Chemical group C1(C(C=CC=C1)C)(C)S(=O)(=O)[O-] GDJZZWYLFXAGFH-UHFFFAOYSA-M 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

HR20020008A 1999-06-04 2002-01-04 Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use HRP20020008A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13781099P	1999-06-04	1999-06-04
PCT/US2000/015188 WO2000075120A1 (en)	1999-06-04	2000-06-02	Diaminothiazoles and their use for inhibiting protein kinases

Publications (1)

Publication Number	Publication Date
HRP20020008A2 true HRP20020008A2 (en)	2004-02-29

Family

ID=22479135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20020008A HRP20020008A2 (en)	1999-06-04	2002-01-04	Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use

Country Status (34)

Country	Link
US (1)	US6620828B2 (uk)
EP (1)	EP1181283B1 (uk)
JP (1)	JP2003501420A (uk)
KR (1)	KR20020015333A (uk)
CN (1)	CN1359380A (uk)
AP (1)	AP2001002341A0 (uk)
AT (1)	ATE288424T1 (uk)
AU (1)	AU778071B2 (uk)
BG (1)	BG106276A (uk)
BR (1)	BR0011585A (uk)
CA (1)	CA2371158A1 (uk)
CZ (1)	CZ20014213A3 (uk)
DE (1)	DE60017894T2 (uk)
EA (1)	EA200101268A1 (uk)
EE (1)	EE200100659A (uk)
ES (1)	ES2234628T3 (uk)
HR (1)	HRP20020008A2 (uk)
HU (1)	HUP0202897A3 (uk)
IL (1)	IL146094A0 (uk)
IS (1)	IS6183A (uk)
MA (1)	MA25530A1 (uk)
MX (1)	MXPA01012483A (uk)
NO (1)	NO20015045L (uk)
NZ (1)	NZ514881A (uk)
OA (1)	OA11959A (uk)
PE (1)	PE20010211A1 (uk)
PL (1)	PL352714A1 (uk)
SK (1)	SK17302001A3 (uk)
SV (1)	SV2002000096A (uk)
UA (1)	UA71971C2 (uk)
UY (1)	UY26190A1 (uk)
WO (1)	WO2000075120A1 (uk)
YU (1)	YU85601A (uk)
ZA (1)	ZA200108291B (uk)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020150921A1 (en) *	1996-02-09	2002-10-17	Francis Barany	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EE200000289A (et) *	1997-10-27	2001-06-15	Agouron Pharmaceuticals, Inc.	Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid
US6262096B1 (en)	1997-11-12	2001-07-17	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
US20040226056A1 (en) *	1998-12-22	2004-11-11	Myriad Genetics, Incorporated	Compositions and methods for treating neurological disorders and diseases
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
BRPI0009721B8 (pt)	1999-04-15	2021-11-23	Bristol Myers Squibb Co	Inibidores de tirosina quinase de proteína cíclica
EP1347971B1 (en)	2000-12-21	2006-03-01	Bristol-Myers Squibb Company	Thiazolyl inhibitors of tec family tyrosine kinases
US6756374B2 (en)	2001-01-22	2004-06-29	Hoffmann-La Roche Inc.	Diaminothiazoles having antiproliferative activity
UA76977C2 (en)	2001-03-02	2006-10-16	Icos Corp	Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
EP1406632A4 (en) *	2001-06-08	2009-11-04	Cytovia Inc	3-ARYL-5-ARYL-1,2,4-OXADIAZOLES AND THEIR ANALOGUES, CASPASE ACTIVATORS AND INDUCERS OF APOPTOSIS, AND USES THEREOF
CA2474322A1 (en) *	2002-01-25	2003-07-31	Kylix Pharmaceuticals B.V.	4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US6818663B2 (en) *	2002-05-17	2004-11-16	Hoffmann-La Roches	Diaminothiazoles
US8450302B2 (en)	2002-08-02	2013-05-28	Ab Science	2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
CN100491374C (zh)	2002-08-02	2009-05-27	Ab科学公司	2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用
BR0315815A (pt)	2002-11-01	2005-09-13	Takeda Pharmaceutical	Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
MXPA05008878A (es) *	2003-02-21	2005-10-05	Pfizer	Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
US7078419B2 (en)	2003-03-10	2006-07-18	Boehringer Ingelheim Pharmaceuticals, Inc.	Cytokine inhibitors
PL3345895T3 (pl)	2003-04-11	2020-05-18	Ptc Therapeutics, Inc.	Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby
EP1618133A1 (en) *	2003-04-17	2006-01-25	Pfizer Inc.	Crystal structure of vegfrkd: ligand complexes and methods of use thereof
EP1644323B1 (en) *	2003-07-07	2015-03-18	Georgetown University	Histone deacetylase inhibitors and methods of use thereof
CA2536954C (en)	2003-08-29	2012-11-27	Exelixis, Inc.	C-kit modulators and methods of use
WO2005037235A2 (en) *	2003-10-16	2005-04-28	Imclone Systems Incorporated	Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
ZA200605624B (en) *	2004-01-12	2007-11-28	Applied Research Systems	Thiazole derivatives and use thereof
JPWO2005108370A1 (ja) *	2004-04-16	2008-03-21	味の素株式会社	ベンゼン化合物
US7211576B2 (en)	2004-04-20	2007-05-01	Hoffmann-La Roche Inc.	Diaminothiazoles
WO2006017216A1 (en) *	2004-07-12	2006-02-16	Merck & Co., Inc.	Histone deacetylase inhibitors
WO2006125805A1 (en) *	2005-05-24	2006-11-30	Laboratoires Serono S.A.	Thiazole derivatives and use thereof
EA017166B1 (ru)	2005-05-24	2012-10-30	Мерк Сероно С.А.	Производные тиазола и их применение
PT1945632E (pt)	2005-11-08	2013-12-24	Vertex Pharma	Moduladores heterocíclicos de transportadores de cassete de ligação a atp
US7691902B2 (en) *	2005-12-28	2010-04-06	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
AU2012244242B2 (en) *	2005-12-28	2015-05-21	Vertex Pharmaceuticals Incorporated	1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
EA200801716A1 (ru) *	2006-01-18	2009-04-28	Амген Инк.	Тиазольные соединения и их применение
JP2009526868A (ja) *	2006-02-15	2009-07-23	アボット・ラボラトリーズ	新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
CN103554095A (zh) *	2006-02-15	2014-02-05	Abbvie公司	新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
BRPI0710213A2 (pt)	2006-03-30	2011-04-12	Ptc Therapeutics Inc	métodos para produzir uma quantidade efetiva de uma proteìna de transleitura funcional codificada por uma sequência de ácido nucleico que compreende uma mutação não-sentido e para tratar, controlar e/ou prevenir uma doença
PE20080401A1 (es)	2006-07-07	2008-06-23	Boehringer Ingelheim Int	DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS
WO2008080134A2 (en) *	2006-12-22	2008-07-03	Rigel Pharmaceuticals, Inc.	4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
US8969386B2 (en)	2007-05-09	2015-03-03	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
CL2008001943A1 (es)	2007-07-02	2009-09-11	Boehringer Ingelheim Int	Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
WO2009003998A2 (en) *	2007-07-02	2009-01-08	Boehringer Ingelheim International Gmbh	Antiproliferative compounds based on 5-membered heterocycles
EP2173728A2 (en)	2007-07-17	2010-04-14	Amgen Inc.	Heterocyclic modulators of pkb
AU2008276512A1 (en) *	2007-07-17	2009-01-22	Amgen Inc.	Thiadiazole modulators of PKB
SI2639224T1 (sl)	2007-12-07	2016-12-30	Vertex Pharmaceuticals Incorporated	Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin
DK3170818T3 (da)	2007-12-07	2020-04-14	Vertex Pharma	Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
JP2011506454A (ja) *	2007-12-13	2011-03-03	グラクソスミスクラインエルエルシー	チアゾールおよびオキサゾールキナーゼ阻害薬
NZ602030A (en)	2008-02-28	2014-02-28	Vertex Pharma	Heteroaryl derivatives as cftr modulators
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
AU2009295855A1 (en)	2008-09-29	2010-04-01	Boehringer Ingelheim International Gmbh	Antiproliferative compounds
US8546433B2 (en)	2009-01-16	2013-10-01	Rigel Pharmaceuticals, Inc.	Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2011048936A1 (ja) *	2009-10-19	2011-04-28	大正製薬株式会社	アミノチアゾール誘導体
JP5871896B2 (ja)	2010-03-26	2016-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂ−ｒａｆキナーゼインヒビター
JP5871897B2 (ja)	2010-03-26	2016-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピリジルトリアゾール
DK3150198T3 (da)	2010-04-07	2021-11-01	Vertex Pharma	Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
US8710055B2 (en)	2010-12-21	2014-04-29	Boehringer Ingelheim International Gmbh	Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2013161919A1 (ja) *	2012-04-26	2013-10-31	小野薬品工業株式会社	Ｔｒｋ阻害化合物
DK2960234T3 (en)	2013-02-19	2019-04-01	Ono Pharmaceutical Co	TRK-INHIBITING CONNECTION
GB201309333D0 (en)	2013-05-23	2013-07-10	Agency Science Tech & Res	Purine diones as WNT pathway modulators
HUE054389T2 (hu)	2013-11-12	2021-09-28	Vertex Pharma	Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
CA2942147C (en)	2014-03-06	2022-12-13	Ptc Therapeutics, Inc.	Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
ES2882656T3 (es)	2014-11-18	2021-12-02	Vertex Pharma	Proceso para realizar pruebas de alto rendimiento de cromatografía líquida de alta resolución
WO2017075312A1 (en)	2015-10-30	2017-05-04	Ptc Therapeutics, Inc.	Methods for treating epilepsy
WO2018052967A1 (en) *	2016-09-13	2018-03-22	Arbutus Biopharma, Inc.	Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
CN111233786B (zh) *	2020-02-04	2021-11-26	中国人民解放军军事科学院军事医学研究院	含五元杂环的苯磺酰胺类化合物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE273062C (de)	1912-04-19	1914-04-20	Deylen Sohn Firma	Vorrichtung zum Schränken von Plattenzündspänen
AU558132B2 (en)	1981-05-27	1987-01-22	Labatt Brewing Co. Ltd.	Malt sterilisation with hydrogen peroxide
WO1986005779A1 (en)	1985-04-03	1986-10-09	Yamanouchi Pharmaceutical Co., Ltd.	Phenylene derivatives
ES2108120T3 (es) *	1991-05-10	1997-12-16	Rhone Poulenc Rorer Int	Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
WO1993019052A1 (en)	1992-03-24	1993-09-30	Merck Sharp & Dohme Limited	3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
US5631156A (en)	1994-06-21	1997-05-20	The University Of Michigan	DNA encoding and 18 KD CDK6 inhibiting protein
EP0788358B1 (en)	1994-11-10	2004-03-31	Millennium Pharmaceuticals, Inc.	Use of pyrazole compounds for the treatment of glomerulonephritis, cancer, atherosclerosis or restenosis
ATE197300T1 (de)	1995-02-02	2000-11-15	Smithkline Beecham Plc	Indolderivate als 5-ht rezeptorantagoniste
US5710173A (en)	1995-06-07	1998-01-20	Sugen, Inc.	Thienyl compounds for inhibition of cell proliferative disorders
AU6526896A (en)	1995-07-22	1997-02-18	Rhone-Poulenc Rorer Limited	Substituted aromatic compounds and their pharmaceutical use
US5705499A (en)	1995-10-06	1998-01-06	Boehringer Ingelheim Pharmaceuticals, Inc.	8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
US5733920A (en)	1995-10-31	1998-03-31	Mitotix, Inc.	Inhibitors of cyclin dependent kinases
US5760028A (en)	1995-12-22	1998-06-02	The Dupont Merck Pharmaceutical Company	Integrin receptor antagonists
US6514971B1 (en)	1996-03-15	2003-02-04	Zeneca Limited	Cinnoline derivatives and use as medicine
EP0816357B1 (en)	1996-06-27	2002-01-09	Pfizer Inc.	Substituted indazole derivatives
EA002113B1 (ru)	1996-09-04	2001-12-24	Пфайзер Инк.	Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
EE200000289A (et) *	1997-10-27	2001-06-15	Agouron Pharmaceuticals, Inc.	Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid
US6391872B1 (en)	1997-11-04	2002-05-21	Pfizer Inc	Indazole bioisostere replacement of catechol in therapeutically active compounds
KR20010031783A (ko)	1997-11-04	2001-04-16	데이비드 존 우드	Ｐｄｅ4 억제제 중 인다졸에 의한 카테콜의 생등입체성치환을 기재로 하는 치료상 활성인 화합물
US6040321A (en) *	1997-11-12	2000-03-21	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
DE69923681T2 (de) *	1998-06-18	2006-01-12	Bristol-Myers Squibb Co.	Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
JP4548642B2 (ja)	1998-09-29	2010-09-22	アメリカン・サイアナミド・カンパニー	プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン

2000
- 2000-02-06 UA UA2001129215A patent/UA71971C2/uk unknown
- 2000-06-02 SK SK1730-2001A patent/SK17302001A3/sk unknown
- 2000-06-02 AU AU57254/00A patent/AU778071B2/en not_active Ceased
- 2000-06-02 EP EP00942660A patent/EP1181283B1/en not_active Expired - Lifetime
- 2000-06-02 WO PCT/US2000/015188 patent/WO2000075120A1/en not_active Application Discontinuation
- 2000-06-02 BR BR0011585-1A patent/BR0011585A/pt not_active IP Right Cessation
- 2000-06-02 PL PL00352714A patent/PL352714A1/xx not_active Application Discontinuation
- 2000-06-02 CN CN00808440A patent/CN1359380A/zh active Pending
- 2000-06-02 KR KR1020017015384A patent/KR20020015333A/ko not_active Application Discontinuation
- 2000-06-02 NZ NZ514881A patent/NZ514881A/en unknown
- 2000-06-02 UY UY26190A patent/UY26190A1/es not_active Application Discontinuation
- 2000-06-02 CA CA002371158A patent/CA2371158A1/en not_active Abandoned
- 2000-06-02 YU YU85601A patent/YU85601A/sh unknown
- 2000-06-02 ES ES00942660T patent/ES2234628T3/es not_active Expired - Lifetime
- 2000-06-02 HU HU0202897A patent/HUP0202897A3/hu unknown
- 2000-06-02 PE PE2000000553A patent/PE20010211A1/es not_active Application Discontinuation
- 2000-06-02 JP JP2001501601A patent/JP2003501420A/ja not_active Abandoned
- 2000-06-02 AP APAP/P/2001/002341A patent/AP2001002341A0/en unknown
- 2000-06-02 EA EA200101268A patent/EA200101268A1/ru unknown
- 2000-06-02 AT AT00942660T patent/ATE288424T1/de not_active IP Right Cessation
- 2000-06-02 CZ CZ20014213A patent/CZ20014213A3/cs unknown
- 2000-06-02 IL IL14609400A patent/IL146094A0/xx unknown
- 2000-06-02 DE DE60017894T patent/DE60017894T2/de not_active Expired - Fee Related
- 2000-06-02 MX MXPA01012483A patent/MXPA01012483A/es not_active Application Discontinuation
- 2000-06-02 OA OA1200100321A patent/OA11959A/en unknown
- 2000-06-02 SV SV2000000096A patent/SV2002000096A/es unknown
- 2000-06-02 EE EEP200100659A patent/EE200100659A/xx unknown
2001
- 2001-02-15 US US09/783,584 patent/US6620828B2/en not_active Expired - Fee Related
- 2001-10-09 ZA ZA200108291A patent/ZA200108291B/xx unknown
- 2001-10-17 NO NO20015045A patent/NO20015045L/no not_active Application Discontinuation
- 2001-11-29 IS IS6183A patent/IS6183A/is unknown
2002
- 2002-01-02 MA MA26465A patent/MA25530A1/fr unknown
- 2002-01-03 BG BG106276A patent/BG106276A/bg unknown
- 2002-01-04 HR HR20020008A patent/HRP20020008A2/hr not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20015045D0 (no)	2001-10-17
KR20020015333A (ko)	2002-02-27
YU85601A (sh)	2004-09-03
AP2001002341A0 (en)	2001-12-31
SK17302001A3 (sk)	2004-01-08
ATE288424T1 (de)	2005-02-15
ZA200108291B (en)	2002-12-24
HUP0202897A2 (hu)	2002-12-28
EP1181283B1 (en)	2005-02-02
EE200100659A (et)	2003-02-17
JP2003501420A (ja)	2003-01-14
HUP0202897A3 (en)	2004-12-28
IL146094A0 (en)	2002-07-25
EA200101268A1 (ru)	2002-06-27
DE60017894T2 (de)	2005-12-29
CZ20014213A3 (cs)	2002-04-17
US20020025976A1 (en)	2002-02-28
PL352714A1 (en)	2003-09-08
MXPA01012483A (es)	2002-07-30
WO2000075120A1 (en)	2000-12-14
OA11959A (en)	2006-04-17
NO20015045L (no)	2002-02-04
NZ514881A (en)	2003-10-31
CA2371158A1 (en)	2000-12-14
IS6183A (is)	2001-11-29
MA25530A1 (fr)	2002-10-01
DE60017894D1 (de)	2005-03-10
UA71971C2 (en)	2005-01-17
BR0011585A (pt)	2002-03-19
PE20010211A1 (es)	2001-03-16
ES2234628T3 (es)	2005-07-01
SV2002000096A (es)	2002-06-07
BG106276A (bg)	2002-10-31
US6620828B2 (en)	2003-09-16
AU5725400A (en)	2000-12-28
EP1181283A1 (en)	2002-02-27
UY26190A1 (es)	2000-12-29
AU778071B2 (en)	2004-11-11
CN1359380A (zh)	2002-07-17

Legal Events

Date	Code	Title
2004-02-29	A1OB	Publication of a patent application
2004-07-30	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2008-12-09	OBST	Application withdrawn

Publication	Publication Date	Title
HRP20020008A2 (en)	2004-02-29	Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use
US6462069B2 (en)	2002-10-08	Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases
RO119463B1 (ro)	2004-11-30	Derivaţi de 4-aminotiazol şi utilizarea lor ca inhibitori ai cdk
EA011691B1 (ru)	2009-04-28	ИМИДАЗО(1,2-a)ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ VEGF-R2
NO322507B1 (no)	2006-10-16	Indazolforbindelser og farmasøytisk materiale derav for inhibering av proteinkinaser, og bruk derav som et medikament.
EP1252146A1 (en)	2002-10-30	Amide compounds for inhibiting protein kinases
US20050288515A1 (en)	2005-12-29	Chemical compounds
JP2021528454A (ja)	2021-10-21	化合物
US6566363B2 (en)	2003-05-20	Pyrazole-thiazole compounds, pharmaceutical compositions containing them
CN104168958A (zh)	2014-11-26	可用于治疗炎症和癌症的二芳基磺酰胺
ES2238463T3 (es)	2005-09-01	Hidroxiimino-fluorenos heterociclicos y uso para inhibir proteina-quinasas.
CN109776520A (zh)	2019-05-21	一种含羧烷基罗丹宁结构的1,3-二芳基吡唑类ptp1b抑制剂及其制备和应用
US20070142437A1 (en)	2007-06-21	Chemical compounds
CZ20001285A3 (cs)	2001-01-17	Substituované 4-aminothiazol-2-ylové sloučeniny jako inhibitory cyklin-dependentních kinas